HOME Study: Hysteroscopic Office Myomectomy Evaluation

Uterine Fibroids Clinical Trial

— HOME  

Official title:

A Hysteroscopic Office Myomectomy Evaluation Using the MyoSure Tissue Removal System for the Removal of Uterine Fibroids and Polyps in the Treatment of Abnormal Uterine Bleeding (AUB)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01152112
• Other study ID #: TMP 2009003
• Status: Active, not recruiting
• Phase: N/A
• First received: June 18, 2010
• Last updated: September 10, 2012
• Start date: June 2010
• Est. completion date: March 2013

Study information

• Verified date: September 2012
• Source: Hologic, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate safety and effectiveness of the MyoSure Tissue Removal System when used by community gynecologists in an office setting for the treatment of patients with symptomatic intrauterine polyps and submucosal fibroids.

Description:

Approximately one hundred subjects will be enrolled in a randomized, comparative setting study conducted at 10-15 investigational sites. Sixty subjects will be randomized to undergo treatment in an office setting, and 40 subjects will be randomized to undergo treatment in a hospital or ambulatory surgical center (ASC) setting. Subjects will undergo a hysteroscopic tissue removal procedure to remove intrauterine polyps, type 0 fibroids, or type I fibroids. Saline infused sonohysterogram images (SIS) obtained at three months post treatment will be compared to pre-treatment images, to determine the percent reduction in target pathology volume. Additionally, subject self-reported pain scores (as rated on an 11 point scale) will compare pain occurring during the treatment procedure to the average pain level experienced during a PAP smear. Economic data will be collected and compared between the two treatment settings.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 86
• Est. completion date: March 2013
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy female between 18 and 55 years of age

• Subject must be able to understand, read and sign the study specific informed consent forms after the nature of the study has been fully explained to her

• Subject is a pre-menopausal or peri-menopausal female, either nulliparous or parous

• Subject is experiencing AUB as confirmed by a symptom raw score of 23 or a calculated symptom score of 44.0 or higher on the Uterine Fibroid Scale and Health Related Quality of Life (UFS-QOL)

• Subject is indicated for myomectomy or polypectomy for benign appearing pathology, based on a hysteroscopic exam and measured by saline infused sonogram assessment within 30 days of the planned index procedure

• Subject exhibits intrauterine polyps and/or submucous myomas which, in the opinion of the treating physician, are compatible with office-based treatment (e.g. 15 minutes or less of cutting time) using the MyoSure device and meet at least one of the following criteria:

• One or more polyps, with at least one of the polyps = 1.5 cm and = 3.0 cm diameter and having broad based attachment to the uterine wall.

• Up to two Type 0 or Type 1 myomas with at least one of the myomas being = 1.5 cm and none of the myomas being 3.0 cm diameter

• If the first myoma is 3.0 cm, the second myoma must be = 2.0 cm

• Fundal myomas must be Type 0

• Polyps plus up to two Type 0 or Type I myomas with at least one of the myomas being = 1.5cm and = 3.0 cm

• The subject demonstrates a negative pregnancy test within 48 hours prior to the planned index procedure

• The subject must document a score of 5 or lower on the Pap Smear and Blood Draw scales of the Pain Tolerance Survey

Exclusion Criteria:

• Subject has known or suspected cancer, including breast, endometrial, and ovarian

• Contraindication and/or allergy to local anesthetic, or oral medications specified in the treatment protocol

• The subject has a history of chronic narcotic use

• Previous uterine artery embolization or other uterine artery occlusion procedure (Doppler or laparoscopic)

• Subject has blood borne pathogens-HIV, hepatitis B, CJD, etc.

• Subject has an IUD at the time of the procedure. A subject may be enrolled in the study if the IUD is removed prior to the treatment procedure

• Subject is taking an anticoagulant or antiplatelet medication other than low dose aspirin

• Active pelvic inflammatory disease or pelvic/vaginal infection

• Subject has a known or suspected coagulopathy or bleeding disorder

• Subject has a history of unmanaged endocrine disease

• Subject has current or past, acute or chronic psychiatric disorder which, in the opinion of the Investigator, may preclude proper evaluation and follow-up

• Subject has a history of auto-immune, inflammatory, or connective tissue disease

• Subject has a history of disease which increases the risk for fluid overload (i.e. significant cardiac, hepatic, or renal dysfunction)

• Uncontrolled hypertension lasting two years or more

• Use of any experimental drug or device within 30 days prior to the screening visit

• The subject has a terminal illness that may prevent the completion of any follow-up assessments

• Any employee or relative of an employee of the Sponsor company or any Investigator site employee or relative of employees working on the study

• Subject has other co-morbid condition(s) that, in the opinion of the Investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study

• Subject has one of the following:

• Type II submucosal myoma

• Type O or Type I submucosal myoma > 3.0 cm

• Fundal Type I myoma

• Highly vascularized myoma as determined by SIS or hysteroscopic examination

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leiomyoma
• Polyps
• Uterine Fibroids

Intervention

Device:
• Myomectomy
Removal of fibroids and / or polyps

Locations

Country	Name	City	State
United States	The Research Division for Integrated Health Services	Ann Arbor	Michigan
United States	Boulder Women's Clinic	Boulder	Colorado
United States	Women's Health Care Practice	Champaign	Illinois
United States	Complete Healthcare for Women	Columbus	Ohio
United States	Kulbresh Women's Center	Irmo	South Carolina
United States	Obstetrics and Gynecology	North Charleston	North Carolina
United States	Phoenix Gynecology Consultants	Phoenix	Arizona
United States	Williams, Benavides, Marston, & Kaminski	Raleigh	North Carolina
United States	Rubino OB/Gyn	West Orange	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Hologic, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent reduction in target pathology volume	Percent reduction in target pathology volume, compared between pre-treatment baseline and month 3 post MyoSure treatment assessments, as measured by saline infused sonohysterogram.	Three months post treatment	No
Secondary	Percent of subjects that achieve 100% removal of target pathology	Percent volume reduction of target pathology between baseline and month three post treatment assessments, as measured by saline infused sonohysterogram.	Three months post treatment	No
Secondary	Subject self-reported pain score occurring during the treatment procedure	Mean difference in pain score compared between subject-rated assessment of pain occurring during a pap smear and pain occurring during the MyoSure treatment procedure, based on the Wong-Baker Faces Rating Scale (FRS)	1 hour post treatment	No